

# CLASSIFIED ADVERTISING

Classified advertising orders, correspondence and payments should be directed to: *JABFP*, Classified Advertising, 1440 Main Street, Waltham, MA 02154.

Classified advertisements placed with *JABFP* are restricted to physician recruitment, faculty positions, CME courses/seminars, and practices for sale. All ads must relate to the medical field and are subject to approval.

Please refer to the schedule below for closing dates. Classified rate is \$1.40 per word (minimum charge of \$75.00 per ad insertion) and \$95.00 per column inch for classified display ads. Prepayment in full is required with all classified advertising. We accept American Express, VISA, or MasterCard. Confidential reply boxes are an additional \$10.00 per insertion. Responses are sent directly every Tuesday and Thursday and the box will remain open for three months.

All advertisements for employment must be nondiscriminatory and comply with all applicable laws and regulations. Ads that discriminate against applicants based on sex, age, race, religion, marital status or physical handicap will not be accepted.

**NOTE:** Our classified advertisements are all set in the same typeface and format. All ads are highlighted by geographic territory.

For more information please call (800) 635-6991 (outside MA), (617) 893-3800 (in MA), Fax # (617) 893-5003.

*Issue Date*  
September-October  
January-February

*Closing Date*  
August 2, 1993  
December 1, 1993

*Issue Date*  
November-December  
March-April

*Closing Date*  
October 1, 1993  
February 1, 1993

## MIDWEST

**NEVADA, MO** — 9-dr group looking for FP interested in including OB in his/her practice. 2 of 5 FPs in group do OB now. We're the only grp in town. Drawing area includes 5 counties, 75,000 pop. Nevada's a family-oriented rural community w/ many outdoor activities nearby — hunting, water sports, etc. Short drive to Kansas City, Springfield, Ozarks, Branson. Please send CV to Rhonda Farmer, Biz Manager, Nevada Medical Clinic, 900 S Adams, Nevada, MO 64772. (417) 667-6015; FAX (417) 667-3007.

**SOUTHERN IL** — FP needed to join female FP sharing offices w/ 2 ortho surgeons. Must be BC/BE and excited about including OB in your practice. Wkend call shared w/ 3rd area FP. Practice includes good mix of genl, ped, OB, general adults. Family-oriented community of 15,000; 15 mi from major state univ, where part-time teaching at med school/residency program is available, if desired. Outdoor recreation prevalent w/ many golf courses, lakes for water sports, hiking, hunting. Competitive salary guar + benefits/bonus. Partnership in two years w/ low buy-in. Send CV to A. Popp, R.D. Morgan & Assoc., 808 W Prairie, Marion, IL 62959. (618) 997-4317; FAX: (618) 997-6992.

## NORTHEAST

**CONNECTICUT SHORELINE** — Well-established urgent care center in Fairfield County seeks physician with strong clinical and leadership capabilities. Direct well-trained staff and enjoy the professional challenge of treating a wide variety of cases from sore throats to minor surgery. Center is owned by a major teaching hospital affiliated with Yale and New York medical colleges. NO CALL! Salary and bonuses can exceed \$130,000. Mike Lane, 1-800-858-4225. Bretner, Clark & Hall, Inc.

**MASSACHUSETTS — CAPE COD** — Where will you be in 2001? Enthusiastic BC/BE FP needed to join optimistic BC FP in beautiful Cape Cod community. Modern, spacious office. Income guarantee of \$85,000. Reply with CV to Floyd McIntyre, M.D., 76 Airline, South Dennis, MA 02660.

**NEW HAMPSHIRE — FAMILY PRACTICE** — Opportunity is available with the affiliated practices of Monadnock Community Hospital in Peterborough, NH. These satellite FP offices handle the primary care and non-urgent care needs of the area. Continuity of care is an essential part of these practices. Weekday office hours. Located in the beautiful Southern Tier of New Hampshire — quaint New England villages and picturesque landscape. Area offers a

slow paced lifestyle with easy access to the larger metro area of Boston (80 miles). For additional information, contact Denise Johnson, spectrum Emergency Care, 1-800-325-3982, ext. 3017.

## PACIFIC

**FAMILY PRACTICE** — Premier multispecialty group near Portland, Oregon has two excellent opportunities for BC/BE family practitioners. Join one of two satellite clinics in which FPs and PAs currently practice. Superb lifestyle, abundant recreational opportunities, and generous benefits package. Send CV to: Karen Stanton, c/o The Vancouver Clinic, 700 NE 87th Ave., Vancouver, WA 98664.

## SOUTHWEST

**SUNSHINE — TUCSON, ARIZONA** — 300 days each year of it in Tucson, Arizona. Seeking Physician Board Certified in Family Practice. Busy, private practice. Call only 1 in 6. Practice located adjacent to full-service hospital. Suburban setting. Highly competitive salary. Possibility of becoming partner in group. Call Marla Elena McElroy, Northwest Hospital, 602-721-5111.

## FRISBIE MEMORIAL

a 120-bed acute care community hospital serving SEACOAST NEW HAMPSHIRE is seeking the following Physicians:

### FAMILY PRACTICE

A fully competitive compensation package tailored to suit the needs of candidate is offered including: Income, Malpractice, Family & Personal Insurance, Vacation, CME, and all necessary operation expenses.

We welcome CVs/inquiries on a continuing basis to:

Frisbie Memorial Hospital  
11 Whitehall Road  
Rochester, NH 03867

Att. S. Droge (603) 774-6504

**CLINICAL FACULTY** — In the Heart of America, Health Midwest, a multi-hospital system in Kansas City, Missouri is actively recruiting Family Practice Faculty members to the Goppert Family Care Center, located in Kansas City, Missouri. Two faculty members who do OB are needed. Candidates must hold M.D. degrees, be Board Certified in Family Medicine, and possess a strong clinical background.

A comfortable lifestyle with affordable housing in an area of rolling hills with four seasons, excellent schools, universities, four-star restaurants, cultural amenities, and major league sporting events awaits you in Kansas City, the City of Fountains.

Please send a curriculum vitae to Marcia Cordell, Vice President, Physician Recruitment, 2316 E. Meyer Boulevard, Kansas City, Missouri 64132.

**N O W A V A I L A B L E**

**NEW!**

# AN ESSENTIAL GUIDE FOR THE PRIMARY CARE PRACTITIONER

Here at last is practical guidance on the primary care of HIV infected patients, collected from recent issues of *AIDS Clinical Care*. This 48-page handbook covers the following topics:

- Identifying patients at risk for HIV infection
- Establishing a primary care relationship
- Taking an initial HIV-related history
- The physical exam in HIV infection
- Laboratory tests for monitoring HIV infection
- Prognostic markers
- Antiretroviral therapy
- Prophylaxis for *Pneumocystis carinii* pneumonia
- Immunizations
- Charting materials
- Overview: Primary care of symptomatic patients
- Approach to symptoms in the outpatient setting
- Preparing for disability and death

**ORDER TOLL FREE  
1-800-843-6356**

Reprints from AIDS CLINICAL CARE

**HIV  
INFECTION**  
A Primary  
Care  
Approach

Frederick  
Bruce

**YES!** Please send me \_\_\_ copies of *HIV Infection: A Primary Care Approach* @ \$9.95 (1 copy); \$8.95 (2-19 copies); \$7.95 (20+ copies). Prices include postage and handling.\*

Enclosed is a check for a total of \$ \_\_\_\_\_

Please charge my \_\_\_ VISA \_\_\_ MasterCard \_\_\_ American Express

Card # \_\_\_\_\_ Exp. Date \_\_\_\_\_

Signature \_\_\_\_\_

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

\*All orders must be prepaid. Make checks payable to:  
**The Massachusetts Medical Society**  
Massachusetts residents must add 5% sales tax. Please allow 4-6 weeks for delivery.

Send to: P.O. Box 9130  
Waltham, MA 02254-9130

Order by FAX: (617) 893-0433 or call  
**TOLL FREE: 1-800-843-6356**

In Massachusetts: 617-893-3800 x1199  
Please inquire about international rates.


ISBN: 0-910133-35-2

SBOH1



The Publishing Division of the  
Massachusetts Medical Society

# You're looking at the answer to your recruitment problems!



It's the *Journal of the American Board of Family Practice*.  
Where you reach the best job candidates. More of them.  
More often. To find out more, just contact Classified  
Advertising at (617) 893-3800.



**The Journal of the American Board of  
Family Practice**

# CARE plants the most wonderful seeds on earth.

Seeds of self-sufficiency that help starving people become healthy, productive people.

And we do it village by village by village.

Please help us turn cries for help  
into the laughter of hope.



**CARE**

1-800-521-CARE

# Sectral<sup>®</sup> 200 mg 400 mg CAPSULES

## acebutolol HCl

The Only Cardioselective Beta Blocker  
Indicated for PVC Control

Usual starting dose	200 mg BID
Optimal PVC response	600 mg to 1200 mg per day
Use in elderly	400 mg to 800 mg per day  Doses above 800 mg per day should be avoided

### (SECTRAL - Brief Summary of prescribing information.)

**CONTRAINDICATIONS:** SECTRAL is contraindicated in: 1) persistently severe bradycardia; 2) second- and third-degree heart block; 3) overt cardiac failure; 4) cardiogenic shock. (See WARNINGS)

**WARNINGS: Cardiac Failure:** Sympathetic stimulation may be essential for support of circulation in patients with diminished myocardial contractility, and inhibition by  $\beta$ -adrenergic receptor blockade may precipitate more severe failure. Although  $\beta$ -blockers should be avoided in overt cardiac failure, SECTRAL can be used cautiously when heart failure is controlled with digitalis and/or diuretics. Digitalis and SECTRAL impair AV conduction. Withdraw SECTRAL if cardiac failure persists. **In Patients Without a History of Cardiac Failure:** In patients with aortic or mitral valve disease or compromised left ventricular function, continued depression of the myocardium with  $\beta$ -blockers over time may lead to cardiac failure. Digitalize patients at first signs of failure, and/or give a diuretic and observe closely. Withdraw SECTRAL if cardiac failure persists.

**Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal:** Abrupt discontinuation of some  $\beta$ -blockers in coronary artery disease patients may exacerbate angina; in some cases, myocardial infarction and death have been reported. Caution such patients against interruption of therapy without a physician's advice. Even in the absence of overt ischemic heart disease, withdraw SECTRAL gradually over a period of about two weeks; observe carefully and advise patients to minimize physical activity during this time. (If desired, patients may be transferred directly to comparable doses of an alternative  $\beta$ -blocker without interruption of  $\beta$ -blocking therapy.) If exacerbation of angina occurs, restart full-dose anti-anginal therapy immediately and hospitalize patient until stabilized.

**Peripheral Vascular Disease:**  $\beta$ -antagonists reduce cardiac output and can precipitate/aggravate arterial insufficiency in patients with peripheral or mesenteric vascular disease. Exercise caution and observe such patients closely for progression of arterial obstruction.

**Bronchoasthmatic Diseases: Patients with Bronchoasthmatic Disease Should, In General, Not Receive a  $\beta$ -Blocker.** Because of its relative  $\beta_1$ -selectivity, low doses of SECTRAL may be used cautiously in such patients who do not respond to, or cannot tolerate, alternative treatment.

Since  $\beta_1$ -selectivity is not absolute and is dose-dependent, use lowest possible dose of SECTRAL initially, preferably in divided doses. Make bronchodilator, e.g., theophylline, or a  $\beta_2$ -stimulant, available in advance with instructions for use.

**Anesthesia and Major Surgery:** The necessity/desirability of withdrawing  $\beta$ -blockers prior to major surgery is controversial; the heart's impaired ability to respond to  $\beta$ -adrenergically mediated reflex stimuli may enhance the risk of excessive myocardial depression during general anesthesia. Difficulty in restarting and maintaining the heartbeat also has been reported with  $\beta$ -blockers. If treatment is continued, take special care when using anesthetics that depress the myocardium; use lowest possible SECTRAL dose. SECTRAL, like other  $\beta$ -blockers, is a competitive inhibitor of  $\beta$ -receptor agonists, so its effects can be reversed by cautious administration of such agents (e.g., dobutamine or isoproterenol). Symptoms of excessive vagal tone (e.g., profound bradycardia, hypotension) may be corrected with atropine.

**Diabetes and Hypoglycemia:**  $\beta$ -blockers may potentiate insulin-induced hypoglycemia and mask some symptoms such as tachycardia; dizziness and sweating are usually not significantly affected. Warn diabetics of possible masked hypoglycemia.

**Thyrotoxicosis:**  $\beta$ -adrenergic blockade may mask some clinical signs (tachycardia) of hyperthyroidism. Abrupt withdrawal of SECTRAL may precipitate a thyroid storm in patients suspected of developing thyrotoxicosis.

**PRECAUTIONS: Impaired Renal or Hepatic Function:** While there are no U.S. studies, foreign published experience shows that acebutolol has been used successfully in chronic renal insufficiency. Acebutolol is excreted via the G.I. tract, but the active metabolite, diacetolol, is eliminated mainly by the kidney. A linear relationship exists between renal clearance of diacetolol and creatinine clearance ( $Cl_{cr}$ ); reduce daily dose of acebutolol by 50% when  $Cl_{cr}$  is less than 50 mL/min and by 75% when it is less than 25 mL/min. Use cautiously in patients with impaired hepatic function.

SECTRAL has been used successfully and without problems in elderly patients in U.S. clinical trials without specific dosage adjustment. However, in the elderly, lower maintenance doses may be required because bioavailability of SECTRAL and its metabolite are approximately doubled.

**Information for Patients:** Warn patients, especially those with evidence of coronary artery disease, against interruption or discontinuation of SECTRAL without physician supervision. Although cardiac failure rarely occurs in properly selected patients, advise patients to consult a physician if signs or symptoms suggestive of impending CHF, or unexplained respiratory symptoms, develop.

Warn patients of possible severe hypertensive reactions from concomitant use of  $\alpha$ -adrenergic stimulants (e.g., nasal decongestants used in OTC cold medicines and nasal drops).

**Clinical Laboratory Findings:** SECTRAL, like other  $\beta$ -blockers, has been associated with development of antinuclear antibodies (ANA). In prospective clinical trials, patients receiving SECTRAL had a dose-dependent increase in the development of positive ANA titers. Symptoms related to this laboratory abnormality were infrequent. Symptoms and ANA titers were reversible upon discontinuation of SECTRAL.

**Drug Interactions:** Catecholamine-depleting drugs may have additive effects when given with  $\beta$ -blockers. Observe patients treated with both agents closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope, presyncope, or orthostatic changes in blood pressure without compensatory tachycardia. Exaggerated hypertensive responses have been reported from use of  $\beta$ -adrenergic antagonists with  $\alpha$ -adrenergic stimulants, including those in OTC cold remedies and vasoconstrictive nasal drops. Nonsteroidal anti-inflammatory drugs may blunt antihypertensive effects of  $\beta$ -blockers.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Chronic oral toxicity studies in rats and mice, at doses 15 times the maximum recommended (60 kg) human dose, did not indicate carcinogenic potential for SECTRAL. Diacetolol, the major metabolite in man, was without carcinogenic potential in rats at doses up to 1800 mg/kg/d. SECTRAL and diacetolol also had no mutagenic potential in the Ames Test. No significant impact on reproductive performance or fertility was found in rats following SECTRAL or diacetolol doses of up to 240 or 1000 mg/kg/d, respectively.

**Pregnancy: Teratogenic Effects:** Pregnancy Category B: No teratogenic effects were seen in rat or rabbit reproduction studies utilizing SECTRAL doses that were, respectively, approximately 31.5 and 6.8 times the maximum recommended human dose. At this dose in the rabbit, slight fetal growth retardation was noted; this was considered to be a result of maternal toxicity (evidenced by reduced food intake, lowered rate of body weight gain, mortality). Diacetolol studies (doses up to 450 mg/kg/d in rabbits and up to 1800 mg/kg/d in rats) showed no evidence of fetal harm other than a significant elevation in postimplantation loss with 450 mg/kg/d, a level at which food consumption and body weight gain were reduced in rabbit dams; there was a nonstatistically significant increase in incidence of bilateral cataract in rat fetuses from dams treated with 1800 mg/kg/d. There are no adequate and well-controlled trials in pregnant women. SECTRAL should be used during pregnancy only if potential benefit justifies risk to the fetus.

**Nonteratogenic Effects:** Human studies indicate that acebutolol and diacetolol cross the placenta. Neonates of mothers who received acebutolol during pregnancy have reduced birth weight, decreased blood pressure, and decreased heart rate.

**Labor and Delivery:** Effect on labor and delivery in pregnant women is unknown. Animal studies have shown no effect of SECTRAL on the usual course of labor and delivery.

**Nursing Mothers:** Acebutolol and diacetolol appear in breast milk (milk:plasma ratio of 7:1 and 12:2, respectively). Use in nursing mothers is not recommended.

**Pediatric Use:** Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS:** SECTRAL is well tolerated in properly selected patients. Most adverse effects have been mild, not required therapy discontinuation, and tended to decrease as treatment duration increases.

The incidence of treatment-related side effects (volunteered and elicited) derived from U.S. controlled clinical trials in patients with hypertension, angina and arrhythmias follows. Numbers represent percentage incidence for SECTRAL (N=1002) versus placebo (N=314), respectively.

**Cardiovascular:** Chest pain 2%, 1%; Edema 2%, 1%. **CNS:** Depression 2%, 1%; Dizziness 6%, 2%; Fatigue 11%, 4%; Headache 6%, 4%; Insomnia 3%, 1%; Abnormal dreams 2%, 1%. **Dermatologic:** Rash 2%, 1%. **Gastrointestinal:** Constipation 4%, 0%; Diarrhea 4%, 1%; Dyspepsia 4%, 1%; Flatulence 3%, 1%; Nausea 4%, 0%. **Genitourinary:** Micturition (frequency) 3%, <1%. **Musculoskeletal:** Arthralgia 2%, 2%; Myalgia 2%, 0%. **Respiratory:** Cough 1%, 0%; Dyspnea 4%, 2%; Rhinitis 2%, <1%. **Special Senses:** Abnormal Vision 2%, 0%.

The following selected (potentially important) side effects were seen in up to 2% of SECTRAL patients: **Cardiovascular:** hypotension, bradycardia, heart failure. **CNS:** anxiety, hyper/hypoesthesia, impotence. **Skin:** pruritus. **Gastrointestinal:** vomiting, abdominal pain. **Genitourinary:** dysuria, nocturia. **Liver and Biliary:** small number of reported cases of liver abnormalities (increased SGOT, SGPT, LDH). In some cases, increased bilirubin or alkaline phosphatase, fever, malaise, dark urine, anorexia, nausea, headache, and/or other symptoms have been reported. In some cases, symptoms and signs were confirmed by rechallenge. Abnormalities were reversible upon drug cessation. **Musculoskeletal:** back and joint pain. **Respiratory:** pharyngitis, wheezing. **Special Senses:** conjunctivitis, dry eye, eye pain. **Autoimmune:** extremely rare reports of systemic lupus erythematosus.

Incidence of drug-related adverse effects (volunteered and solicited) based on SECTRAL dose is shown below. (Data from 266 hypertensive patients treated for 3 months on a constant dose.)

Body System	400 mg/day (N=132)	800 mg/day (N=63)	1200 mg/day (N=71)
Cardiovascular	5%	2%	1%
Gastrointestinal	3%	3%	7%
Musculoskeletal	2%	3%	4%
Central Nervous System	9%	13%	17%
Respiratory	1%	5%	6%
Skin	1%	2%	1%
Special Senses	2%	2%	8%
Genitourinary	2%	3%	1%

**Potential Adverse Effects:** Certain adverse effects not listed above have been reported with other  $\beta$ -blocking agents and should be considered as potential adverse effects of SECTRAL.

**CNS:** Reversible mental depression progressing to catatonia, an acute syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuro-psychometrics.

**Cardiovascular:** Intensification of AV block (see CONTRAINDICATIONS).

**Allergic:** Erythematous rash, fever with aching and sore throat, laryngospasm, respiratory distress.

**Hematologic:** Agranulocytosis, nonthrombocytopenic and thrombocytopenic purpura, **Gastrointestinal:** Mesenteric arterial thrombosis, ischemic colitis.

**Miscellaneous:** Reversible alopecia, Pilonius disease. The oculomucocutaneous syndrome associated with praxolol has not been reported with SECTRAL.

**Keep at room temperature. Approximately 25°C (77°F).**

3482-6 B/13/92

### Reference:

1. Data on file, Wyeth-Ayerst Laboratories.

WYETH-AYERST  
LABORATORIES  
PO Box 269, PA 19121

Printed in U.S.A.

21009R